Vertex Pharmaceuticals (VRTX) Projected to Post Earnings on Thursday

Vertex Pharmaceuticals (NASDAQ:VRTX) is expected to be announcing its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $5.05 per share and revenue of $3.1762 billion for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating the consensus estimate of $4.58 by $0.22. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. Vertex Pharmaceuticals’s revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the business posted $4.38 EPS. On average, analysts expect Vertex Pharmaceuticals to post $16 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $470.52 on Thursday. The company has a market capitalization of $119.38 billion, a P/E ratio of 33.18 and a beta of 0.30. The company has a 50 day simple moving average of $456.21 and a 200-day simple moving average of $427.39. Vertex Pharmaceuticals has a 1 year low of $362.50 and a 1 year high of $519.68.

Insider Activity

In related news, EVP Ourania Tatsis sold 4,500 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $474.99, for a total value of $2,137,455.00. Following the completion of the transaction, the executive vice president owned 42,293 shares in the company, valued at approximately $20,088,752.07. The trade was a 9.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Charles F. Wagner, Jr. sold 14,000 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the sale, the executive vice president owned 37,725 shares in the company, valued at approximately $17,202,600. This trade represents a 27.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 165,105 shares of company stock valued at $73,858,523. 0.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VRTX. Kelleher Financial Advisors acquired a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at about $39,000. Triumph Capital Management purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter worth approximately $43,000. JPL Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $50,000. Clark Capital Management Group Inc. lifted its stake in Vertex Pharmaceuticals by 18.9% in the third quarter. Clark Capital Management Group Inc. now owns 572 shares of the pharmaceutical company’s stock worth $224,000 after acquiring an additional 91 shares during the last quarter. Finally, Gamco Investors INC. ET AL purchased a new position in Vertex Pharmaceuticals in the second quarter worth approximately $228,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on VRTX. JPMorgan Chase & Co. raised their target price on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. Scotiabank assumed coverage on Vertex Pharmaceuticals in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $495.00 price objective for the company. Leerink Partners boosted their price objective on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a report on Monday, December 29th. Morgan Stanley set a $564.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, December 5th. Finally, Barclays raised shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $414.00 to $606.00 in a research note on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $522.68.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.